16 to 18-hour infusions of eptifibatide seem optimal in reducing ischemic complications following percutaneous coronary intervention
Publication
, Journal Article
Rebeiz, AG; Pieper, KS; O'Shea, JC; Gilchrist, IC; Chandler, B; Slater, J; Muhlestein, JB; Lorenz, TJ; Joseph, D; Kitt, MM; Tcheng, JE
Published in: CIRCULATION
October 23, 2001
Duke Scholars
Published In
CIRCULATION
ISSN
0009-7322
Publication Date
October 23, 2001
Volume
104
Issue
17
Start / End Page
386 / 386
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Rebeiz, A. G., Pieper, K. S., O’Shea, J. C., Gilchrist, I. C., Chandler, B., Slater, J., … Tcheng, J. E. (2001). 16 to 18-hour infusions of eptifibatide seem optimal in reducing ischemic complications following percutaneous coronary intervention. CIRCULATION, 104(17), 386–386.
Rebeiz, A. G., K. S. Pieper, J. C. O’Shea, I. C. Gilchrist, B. Chandler, J. Slater, J. B. Muhlestein, et al. “16 to 18-hour infusions of eptifibatide seem optimal in reducing ischemic complications following percutaneous coronary intervention.” CIRCULATION 104, no. 17 (October 23, 2001): 386–386.
Rebeiz AG, Pieper KS, O’Shea JC, Gilchrist IC, Chandler B, Slater J, et al. 16 to 18-hour infusions of eptifibatide seem optimal in reducing ischemic complications following percutaneous coronary intervention. CIRCULATION. 2001 Oct 23;104(17):386–386.
Rebeiz, A. G., et al. “16 to 18-hour infusions of eptifibatide seem optimal in reducing ischemic complications following percutaneous coronary intervention.” CIRCULATION, vol. 104, no. 17, LIPPINCOTT WILLIAMS & WILKINS, Oct. 2001, pp. 386–386.
Rebeiz AG, Pieper KS, O’Shea JC, Gilchrist IC, Chandler B, Slater J, Muhlestein JB, Lorenz TJ, Joseph D, Kitt MM, Tcheng JE. 16 to 18-hour infusions of eptifibatide seem optimal in reducing ischemic complications following percutaneous coronary intervention. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2001 Oct 23;104(17):386–386.
Published In
CIRCULATION
ISSN
0009-7322
Publication Date
October 23, 2001
Volume
104
Issue
17
Start / End Page
386 / 386
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology